Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCC-CRM-MCM Vaccines B.V.-diphtheria-tetanus-pertussis-poliomyelitis-Haemophilus influenzae type b infection-hepatitis B-meningococcal meningitis (serogroup C)
- Development stage
- Unknown
- Lead developer
- MCM Vaccine Co
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This designation refers to a specific immunization regimen evaluated in clinical trials, consisting of the concomitant administration of the hexavalent vaccine VAXELIS (V419) and a meningococcal serogroup C conjugate vaccine (MCC-CRM). VAXELIS, developed by MCM Vaccines B.V. (a joint venture between Merck and Sanofi), is a combination vaccine containing diphtheria and tetanus toxoids, acellular pertussis antigens, inactivated poliovirus, Haemophilus influenzae type b conjugate (PRP-OMPC), and recombinant hepatitis B surface antigen. The MCC-CRM component is a separate vaccine targeting Neisseria meningitidis serogroup C, using the CRM197 carrier protein. This co-administration approach is designed to simplify infant immunization schedules by providing protection against seven major pediatric pathogens in a single visit.
- Brand names
- VAXELIS
- Other names
- DTaP-IPV-Hib-HepB + MenC-CRM
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)HBsAg (Hepatitis B surface antigen)OMPC (Meningococcal outer membrane protein complex)Neisseria meningitidis group C capsular polysaccharidePRN (Pertactin)TT (Tetanus toxoid)Fimbrial antigen type 3
Beyond the preview
Go deeper on MCC-CRM-MCM Vaccines B.V.-diphtheria-tetanus-pertussis-poliomyelitis-Haemophilus influenzae type b infection-hepatitis B-meningococcal meningitis (serogroup C).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCC-CRM-MCM Vaccines B.V.-diphtheria-tetanus-pertussis-poliomyelitis-Haemophilus influenzae type b infection-hepatitis B-meningococcal meningitis (serogroup C).